No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KBR240816P72500
- 4.60
- 0.000.00%
15min DelayClose Jul 22 14:09 ET
4.60High4.60Low
4.60Open4.60Pre Close1 Volume0 Open Interest72.50Strike Price460.00Turnover36.76%IV0.70%PremiumAug 16, 2024Expiry Date4.12Intrinsic Value100Multiplier25DDays to Expiry0.48Extrinsic Value100Contract SizeAmericanOptions Type-0.7041Delta0.0541Gamma13.41Leverage Ratio-0.0393Theta-0.0283Rho-9.44Eff Leverage0.0619Vega
Intraday
- 5D
- Daily
News
Express News | KBR Says Its Blue Ammonia Technology Selected By Shell For Its Blue Horizons Low-Carbon Hydrogen And Ammonia Project In Duqm, Oman
KBR's Blue Ammonia Technology Selected for Shell Blue Horizons Project in Oman
KBR (NYSE: KBR) announced today its blue ammonia technology has been selected by Shell for its Blue Horizons low-carbon hydrogen and ammonia project...
KBR, Inc.'s (NYSE:KBR) Subdued P/S Might Signal An Opportunity
With a median price-to-sales (or "P/S") ratio of close to 1.6x in the Professional Services industry in the United States, you could be forgiven for feeling indifferent about KBR, Inc.'s (NYSE:KBR)
Unusual Options Activity: DASH, CCK and Others Attract Market Bets, DASH V/OI Ratio Reaches 279.3
EST Jul 18th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
KBR to Acquire LinQuest for $737M, Fortifies Technology Business
In a bid to expand opportunities for revenue growth and meet customer and market demands, KBR, Inc. (KBR Quick QuoteKBR - Free Report) recently inked a deal to acquire an engineering, data analytics and digital integration company — LinQuest Corporation.
Express News | KBR Awarded Advisory Consulting Contract for Kuwait Oil Company's Renewables and Hydrogen Masterplan Project
Comments
KBR's revenue growth could be seen as a positive sign, despite potential sacrifice of current earnings per share. Future earnings are crucial for shareholders. Despite slower share price gains, the business may continue to perform well.
Those Who Invested in KBR (NYSE:KBR) Five Years Ago Are up 238%Given the upward trend and increased efficiency in KBR's return on capital employed, it appears to show promise. Considering the outstanding shareholder returns over the last five years, it's advisable for investors to explore if these trends will continue.
Sizable insider selling at KBR creating investor caution. Lack of insider buying combined with substantial selling seen as red flag. 1.0% insider ownership doesn't fully dispel concerns.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
Gap Ups
1. $ON Semiconductor(ON.US$ - up 3.0%
2. $JPMorgan(JPM.US$ - up 1.8%
3. $Uber Technologies(UBER.US$ - up 1.6%
4. $KBR Inc(KBR.US$ - up 0.8%
5. $Wells Fargo & Co(WFC.US$ - up 0.7%
6. $James Hardie Industries(JHX.US$ - up 0.5%
7. $Celsius Holdings(CELH.US$ - up 0.5%
8....
+9
11
Gainers:
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
• $Rocket Pharmaceuticals(RCKT.US$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $Canada Goose(GOOS.US$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
12
Read more